Loading
MM014 is an in vivo CAR-T programme from Mucommune for solid tumours, in early laboratory development.
MM014 is listed on the pipeline page of Mucommune as an in vivo CAR-T programme for solid tumours, under its in vivo cell engineering platform. The company does not state the target or the stage on that page, and no clinical trial is registered.
Described by the company as in vivo CAR-T for solid tumours: the patient's T cells are engineered inside the body rather than in a manufacturing facility.
1.MM014 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"MM014" OR ABSTRACT:"MM014") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MM014, not a curated reading list.
Shares In vivo CAR-T and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/